Alembic Pharmaceuticals Limited (Alembic)
has received final approval from the US Food & Drug Administration
(USFDA) for its Abbreviated New Drug Application (ANDA) Travoprost
Ophthalmic Solution USP, 0.004%.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Travatan Ophthalmic Solution, 0.004%, of Alcon Pharmaceuticals Limited (Alcon).
Travoprost Ophthalmic Solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Alembic has a cumulative total of 110 ANDA approvals (97 final approvals and 13 tentative approvals) from USFDA, the company said in the filing.
Stock view:
Alembic Pharmaceuticals Ltd is currently trading at Rs541.85, up by Rs1.5 or 0.28% from its previous closing of Rs540.35 on the BSE.
The scrip opened at Rs540 and has touched a high and low of Rs547 and Rs538 respectively.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Travatan Ophthalmic Solution, 0.004%, of Alcon Pharmaceuticals Limited (Alcon).
Travoprost Ophthalmic Solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Alembic has a cumulative total of 110 ANDA approvals (97 final approvals and 13 tentative approvals) from USFDA, the company said in the filing.
Stock view:
Alembic Pharmaceuticals Ltd is currently trading at Rs541.85, up by Rs1.5 or 0.28% from its previous closing of Rs540.35 on the BSE.
The scrip opened at Rs540 and has touched a high and low of Rs547 and Rs538 respectively.
0 comments:
Post a Comment
Please add comment